GlassScriptPhysician profile
David J Braun
NPI 1700806973
$7,463.45
in general payments reported to CMS, 2019-2025
20 companies · $662 in 2025
The $662 reported for 2025 was more than what 77% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,023 · 2020: $251 · 2021: $2,584 · 2022: $841 · 2023: $1,324 · 2024: $779 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,764.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,679.47 | 2019-2025 | Precision 1, Total30, Dailies Total1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,147.09 | 2019-2021 | |
| Coopervision INC. | $1,016.62 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Sun Pharmaceutical Industries INC. | $480.96 | 2019-2024 | Cequa |
| Sight Sciences, INC. | $385.90 | 2021-2023 | Tearcare System |
| Bausch & Lomb Americas INC. | $318.63 | 2022-2025 | Infuse |
| Biotissue Holdings INC. | $219.75 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $210.45 | 2024-2025 | Xdemvy |
| Amgen INC. | $195.17 | 2024-2025 | Tepezza |
| Dompe US, INC. | $177.88 | 2024-2025 | Oxervate |
| Shire North American Group INC | $121.38 | 2019 | |
| Horizon Therapeutics Plc | $113.03 | 2023 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $90.79 | 2019-2024 | |
| Tearlab Corp | $77.22 | 2022 | |
| Abb Con-Cise Optical Group LLC | $71.19 | 2022-2024 | Spectacle Lenses, Contact Lens |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $52.98 | 2019-2020 | |
| Abbvie INC. | $47.76 | 2022-2023 | Lumigan, Vuity |
| Thea Pharma INC. | $23.97 | 2023 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $13.81 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Braun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.